MedElevator Войти в исследования
← Поиск публикаций

DOI 10.2147/pgpm.s619780

Медицинская библиотека · Pharmacogenomics and personalized medicine · 2026

Five VEGFA Polymorphisms and Bleeding During Warfarin Therapy in a Saudi Population: An Exploratory Retrospective Cohort Study.

Holail Jasmine, Mobarak Reem, Al-Ghamdi Bandar, El Shamieh Said, Tamim Hani, Kanaan Ziad Ahmad, Fakhoury Hana M A, Alkattan Khaled

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Warfarin remains a widely used anticoagulant for long-term thromboprophylaxis, but its narrow therapeutic index and substantial interindividual variability increase the risk of bleeding complications. Functional variants in vascular endothelial growth factor A (VEGFA) may therefore influence vascular integrity during anticoagulant therapy. This study investigated the association between functional VEGFA polymorphisms and warfarin-associated bleeding in a Saudi cohort.

METHODS

In this retrospective cohort study, 161 Saudi patients receiving stable maintenance warfarin therapy were genotyped for five VEGFA single-nucleotide polymorphisms (SNPs): rs699947, rs833069, rs2010963, rs35410204, and rs866236. Clinical characteristics and bleeding events during warfarin therapy were obtained from electronic medical records. Bleeding status was determined from clinically documented bleeding events during warfarin therapy that required medical evaluation, hospitalization, or blood transfusion. Genotype-phenotype associations were assessed using chi-square analysis and a multivariable logistic regression model.

RESULTS

Bleeding occurred in 39% of the patients (63/161). Among the five VEGFA variants studied, rs699947 and rs833069 showed associations with bleeding in bivariate analysis. The rs699947 A/A genotype and rs833069 T/T genotype were less frequent in patients with bleeding than in those without bleeding (6.7% vs 25.5%, p = 0.009; and 16.4% vs 37.5%, p = 0.013, respectively). The rs833069 association did not survive Bonferroni correction for multiple testing and is therefore considered exploratory. Following adjustment for age, sex, body mass index, international normalized ratio, systolic blood pressure, and diastolic blood pressure, rs699947 remained significantly associated with bleeding. For rs833069, the overall genotype association remained statistically significant; however, individual genotype comparisons were not statistically significant. For rs699947, the A/A genotype was associated with lower odds of bleeding compared with the C/C genotype (OR 0.249, 95% CI 0.062-0.999; p = 0.050). No significant associations were observed for rs2010963, rs35410204, or rs866236.

CONCLUSION

In this exploratory retrospective cohort study, VEGFA rs699947 and rs833069 showed possible associations with bleeding during warfarin therapy in Saudi patients. These findings provide preliminary evidence that VEGFA polymorphisms may contribute to bleeding susceptibility during warfarin therapy. Given the modest sample size, these findings should be interpreted cautiously and require validation in larger prospective studies.

Для цитирования: Holail Jasmine, Mobarak Reem, Al-Ghamdi Bandar, El Shamieh Said, Tamim Hani, Kanaan Ziad Ahmad, Fakhoury Hana M A, Alkattan Khaled. Five VEGFA Polymorphisms and Bleeding During Warfarin Therapy in a Saudi Population: An Exploratory Retrospective Cohort Study.. Pharmacogenomics and personalized medicine. 2026. DOI: 10.2147/pgpm.s619780.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.